ANALISA DAMPAK EKONOMI, SOSIAL, LINGKUNGAN TERHADAP PENGEMBANGAN OBJEK WISATA BANYU BIRU DI DESA SUMBEREJO, WINONG, PASURUAN JATIM

Pariwisata merupakan salah satu sektor untuk meningkatkan pendapatan asli daerah (PAD). Keberadaan objek wisata memberikan dampak pada masyarakat lokal yang area objek wisata.Penelitian ini bertujuan untuk mengetahui dan Analisa dampak ekonomi, sosial, lingkungan terhadap pengembangan objek wisata Banyu Biru di Desa Sumberrejo, Winongan, Pasuruan Jatim. Alat analisis menggunakan kuesioner dengan sampel 61 respoden stakeholderdimana menghasilkan nilai R 0.961, menunjukkan hubungan antara dua variabel adalah kuat, ditandai dengan nilai R2 sebesar 0.923 atau 92,3%, sehingga dampak ekonomi, sosial dan lingkungandapat menjelaskan pengembangan objek wisata banyu biru 7.7% dijelaskan oleh variabel lain. Berdasarkan hasil uji F variabel dampak ekonomi, sosial dan lingkunganberpengaruh signifikan terhadap pengembangan objek wisata dibuktikan dari hasil nilai fhitung sebesar 227.659 dan ftabel sebesar 2.77 pada tingkat signifikansi sebesar 0.000 (0%) atau lebih kecil dari 5%.. hasil uji t menyebutkan dampak ekonomiparsial berpengaruh signifikan terhadap pengembangan objek wisatadengan nilai thitung sebesar 1.735 atau 17.35% lebih kecil dari t tabel sebesar 1.672 dengan nilai signifikansi sebesar 0.088. sosialsecara parsial berpengaruh signifikan terhadap pengembangan objek wisata dengan nilai thitung sebesar 2.280 atau 22.80% lebih kecil dari ttabel sebesar 1.672 dengan nilai signifikansi sebesar 0.026. lingkungansecara parsial berpengaruh signifikan terhadap pengembangan objek wisatadengan nilai thitung sebesar 12.188 atau 121.88% lebih besar dari ttabel sebesar 1.672 dengan tingkat signifikansi sebesar 0.000. variabel lingkunganyang paling signifikan terhadap pengembangan objek wisata dengan nilai thitung paling tinggi yaitu 12.188 atau 121.88% dengan tingkat signifikan 0.000

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research